142 related articles for article (PubMed ID: 16557018)
1. [Evaluation of mouse brain-derived, inactivated Japanese encephalitis vaccine].
Kurane I
Uirusu; 2005 Dec; 55(2):307-12. PubMed ID: 16557018
[TBL] [Abstract][Full Text] [Related]
2. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
[TBL] [Abstract][Full Text] [Related]
3. [Background of recent JE vaccine issues].
Okabe N
Uirusu; 2005 Dec; 55(2):303-6. PubMed ID: 16557017
[TBL] [Abstract][Full Text] [Related]
4. Allergic reactions to Japanese encephalitis vaccine.
Plesner AM
Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
[TBL] [Abstract][Full Text] [Related]
7. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
8. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.
Rabe IB; Miller ER; Fischer M; Hills SL
Vaccine; 2015 Jan; 33(5):708-12. PubMed ID: 25498208
[TBL] [Abstract][Full Text] [Related]
9. Safety of Japanese encephalitis vaccines.
Hu YL; Lee PI
Hum Vaccin Immunother; 2021 Nov; 17(11):4259-4264. PubMed ID: 34613870
[TBL] [Abstract][Full Text] [Related]
10. Product review on the JE vaccine IXIARO.
Firbas C; Jilma B
Hum Vaccin Immunother; 2015; 11(2):411-20. PubMed ID: 25621812
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
[TBL] [Abstract][Full Text] [Related]
12. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Appaiahgari MB; Vrati S
Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
[TBL] [Abstract][Full Text] [Related]
13. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Fischer M; Lindsey N; Staples JE; Hills S;
MMWR Recomm Rep; 2010 Mar; 59(RR-1):1-27. PubMed ID: 20224546
[TBL] [Abstract][Full Text] [Related]
14. Current recommendations for the Japanese encephalitis vaccine.
Chen HL; Chang JK; Tang RB
J Chin Med Assoc; 2015 May; 78(5):271-5. PubMed ID: 25841620
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysis.
Furuya-Kanamori L; Xu C; Doi SAR; Clark J; Wangdi K; Mills DJ; Lau CL
Vaccine; 2021 Jul; 39(32):4429-4436. PubMed ID: 34175128
[TBL] [Abstract][Full Text] [Related]
16. Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (IXIARO
Amicizia D; Zangrillo F; Lai PL; Iovine M; Panatto D
J Prev Med Hyg; 2018 Mar; 59(1):E99-E107. PubMed ID: 29938245
[TBL] [Abstract][Full Text] [Related]
17. T-cell activation and induction of antibodies and memory T cells by immunization with inactivated Japanese encephalitis vaccine.
Aihara H; Takasaki T; Toyosaki-Maeda T; Suzuki R; Okuno Y; Kurane I
Viral Immunol; 2000; 13(2):179-86. PubMed ID: 10892998
[TBL] [Abstract][Full Text] [Related]
18. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis.
Erra EO; Kantele A
Expert Rev Vaccines; 2015; 14(9):1167-79. PubMed ID: 26162529
[TBL] [Abstract][Full Text] [Related]
19. Use of the live attenuated Japanese Encephalitis vaccine SA 14-14-2 in children: A review of safety and tolerability studies.
Ginsburg AS; Meghani A; Halstead SB; Yaich M
Hum Vaccin Immunother; 2017 Oct; 13(10):2222-2231. PubMed ID: 28841362
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for the use of Japanese encephalitis vaccines.
Lee PI; Huang YC; Hwang KP; Liu CC; Chiu CH; Chen PY; Lu CY; Chen CJ; Chang LY; Chiu NC; Chi H; Lin HC; Wu KG; Ho YH; Sun W; Lin TY
Pediatr Neonatol; 2020 Feb; 61(1):3-8. PubMed ID: 31870559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
